Pearl McElfish named associate director of community outreach and engagement at UAMS Winthrop P. Rockefeller Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pearl McElfish was named associate director of community outreach and engagement at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.

McElfish’s position will involve creating a state-wide community network to support rural and minority communities for cancer prevention, education, navigation to treatment and survivorship.

She previously was vice chancellor for the UAMS Northwest Regional Campus in Fayetteville.

McElfish is the founder of the Office of Community Health and Research and the Center for Pacific Islander Health at UAMS. 

Her research focuses on reducing health disparities among rural and minority communities. She also conducts methodological research related to the conducting community-based participatory research and dissemination of findings to community stakeholders.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login